Inovio misses Q3 revenues; CSL rebrands its flu vaccines business;

> Inovio ($INO) missed a Q3 consensus revenue estimate of $29 million from Zack's, instead bringing in $24.2 million. Earnings report

> CSL announced that its flu vaccines business will operate under the brand Seqirus. Release

> France-based Valneva's U.S. subsidiary, Intercell USA, has entered into a distribution and marketing services agreement with VaxServe, a Sanofi Pasteur company, for Valneva's Japanese encephalitis vaccine. Release

> Researchers at Washington University in St. Louis have identified broadly neutralizing antibodies that protect against infection from a range of alphaviruses, including Chikungunya virus. Release

> Caladrius Biosciences ($CLBS) presented additional data at the Society for Immunotherapy of Cancer Annual Meeting supporting its lead candidate for the treatment of metastatic melanoma. Release

Suggested Articles

Amid the COVID-19 pandemic, many teams of researchers are working on potential vaccines. We asked experts to assess progress—and point out challenges.

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.

Pfizer posted positive top-line results for a trial of its 20-valent pneumococcal vaccine, potentially setting up a filing by the end of 2020.